950210.KO Prestige BioPharma Limited
- Market cap
- KRW 234B
- P/E
- -
- P/B
- 0.56x
- ROE
- -21.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is 950210.KO undervalued?
Graham numberThe Graham number of Prestige BioPharma Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Prestige BioPharma Limited fundamental analysis
No fundamental analysis for Prestige BioPharma Limited yet.
Prestige BioPharma Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Prestige BioPharma Limited
Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, antibody drugs, and vaccines in Singapore. The company offers Trastuzumab biosimilar for the treatment of breast cancer; Bevacizumab biosimilar for the treatment in oncology; and PBP1502, an adalimumab biosimilar, which is in Phase 1 clinical trial for the treatment in immunity. It also develops PBP1510, a first-in-class antibody, which is in phase 1…
Full company profilePrestige BioPharma Limited financial statements
Prestige BioPharma Limited annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | - | 2.09B | - | - | - | 162M | 689M | 14.3B | 26.1B |
| Gross Profit | -240M | 1.33B | -1.19B | -1.67B | -3.87B | 128M | -529M | -24.0B | -16.4B |
| Operating Income | -3.24B | -4.40B | -10.9B | -18.4B | -119B | 1.03B | -62.8B | -67.3B | -93.6B |
| EBITDA | -1.99B | -686M | -13.7B | -5.68B | -207B | 10.5B | -31.0B | 33.3B | -83.4B |
| Net Income | -2.23B | -1.45B | -15.0B | -7.39B | -211B | 17.6B | -32.9B | 22.3B | -91.5B |
| EPS | -7.42 | -4.82 | -50 | -136 | -3,519 | 292 | -548 | 371 | -7,613 |
| Balance Sheet | |||||||||
| Total Assets | 41.2B | 103B | 160B | 604B | 500B | 742B | 712B | 742B | 738B |
| Total Liabilities | 13.3B | 44.7B | 22.3B | 29.2B | 69.9B | 195B | 196B | 236B | 233B |
| Shareholders' Equity | 28.0B | 58.2B | 138B | 575B | 430B | 451B | 439B | 409B | 432B |
| Cash & Short-term Investments | 3.72B | 9.83B | 48.4B | 459B | 303B | 301B | 229B | 174B | 62.7B |
| Total Debt | 6.79B | 18.5B | 2.88B | 7.77B | 4.25B | 86.2B | 89.7B | 144B | - |
| Cash Flow | |||||||||
| Operating Cash Flow | -1.87B | 3.78B | -12.4B | -15.4B | -45.9B | -60.3B | -48.0B | -54.3B | -55.8B |
| Capital Expenditure | 17.2B | 35.4B | 18.7B | 18.1B | 68.1B | 65.6B | 28.0B | 40.7B | 11.5B |
| Free Cash Flow | -19.1B | -31.6B | -31.2B | -33.6B | -114B | -126B | -76.0B | -95.0B | -67.3B |
| Ratios | |||||||||
| ROE | -8.0% | -2.5% | -10.9% | -1.3% | -49.2% | 3.9% | -7.5% | 5.4% | -21.2% |
| ROA | -5.4% | -1.4% | -9.4% | -1.2% | -42.3% | 2.4% | -4.6% | 3.0% | -12.4% |
| Net Profit Margin | - | -69.3% | - | - | - | 10,855.9% | -4,777.6% | 155.6% | -351.0% |
| Debt to Equity | 0.24x | 0.32x | 0.02x | 0.01x | 0.01x | 0.19x | 0.20x | 0.35x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Prestige BioPharma Limited dividends
Prestige BioPharma Limited has not paid dividends in the last 9 fiscal years.
Who owns Prestige BioPharma Limited
- Insiders 0.00%
- Institutions 0.03%
- Public & others 99.97%
- Shares outstanding 60.1M
- Free float 17.7M
Prestige BioPharma Limited company profile
- Company name
- Prestige BioPharma Limited
- Ticker
- 950210.KO
- ISIN
- KR8702070002
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 64
- Fiscal year end
- June
- Address
- #04-24 Nucleos South Building, Singapore, Singapore, 138567
- Phone
- 65 6924 6535
- Website
- prestigebiopharma.com
About Prestige BioPharma Limited
Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, antibody drugs, and vaccines in Singapore. The company offers Trastuzumab biosimilar for the treatment of breast cancer; Bevacizumab biosimilar for the treatment in oncology; and PBP1502, an adalimumab biosimilar, which is in Phase 1 clinical trial for the treatment in immunity. It also develops PBP1510, a first-in-class antibody, which is in phase 1/2a clinical trial for the treatment of pancreatic cancer; PBP1710, a first-in-class antibody that is in preclinical trials for the treatment of solid tumor and fibrosis; and IDC007, a bispecific antibody for the treatment of CRS. In addition, the company is developing IDC005, IDC001, IDC002, IDC003, IDC008, and IDC009 bispecific antibodies; IDC111, a first-in-class antibody; IDC112, first-in-class antibody; IDC113 first-in-class antibody; IDC332, IDC331, IDC333, and IDC334 novel concept antibodies; and IDC441, an ADC antibody for the treatment of solid tumours. Additionally, it offers biosimilars for immunology, endocrinology, oncology, haematology, and dermatology diseases. Further, it develops IDC221, a PAUF-based pancreatic cancer diagnostic solution for the treatment of pancreatic cancers. Prestige BioPharma Limited was incorporated in 2015 and is headquartered in Singapore.
Prestige BioPharma Limited management
9- Ms. So-Yeon ParkChairman & CEO · born 1963
- Mr. Jinwoo KimVice Chairman of the Board & CFO · born 1964
- Mr. Dong -Jo ShinHead of Finance · born 1973
- Mr. Michael RuppertHead of Business Development · born 1967
- Neil O'ConnorCMCB Head
- Sumita PradhanR&MA Head
- Ms. Sumiko ShibaSecretary · born 1982
- Ms. Kay K.H. LeeClinical Development Manager · born 1970
- Mr. Ghislain M.C BonamyGeneral Manager of Licensing · born 1979